Urogen Pharma Target of Unusually Large Options Trading (NASDAQ:URGN)

Urogen Pharma (NASDAQ:URGN) saw unusually large options trading activity on Wednesday. Investors bought 20,427 call options on the company. This represents an increase of approximately 2,706% compared to the average daily volume of 728 call options.

Urogen Pharma Stock Down 1.4%

Shares of URGN traded down $0.32 on Wednesday, hitting $23.15. 345,783 shares of the stock traded hands, compared to its average volume of 1,419,126. Urogen Pharma has a 1 year low of $3.42 and a 1 year high of $30.00. The stock’s 50 day moving average is $22.01 and its two-hundred day moving average is $18.27. The firm has a market capitalization of $1.08 billion, a P/E ratio of -6.70 and a beta of 1.21.

Urogen Pharma (NASDAQ:URGN) last released its earnings results on Thursday, November 6th. The company reported ($0.69) EPS for the quarter, topping the consensus estimate of ($0.72) by $0.03. Urogen Pharma had a negative net margin of 170.59% and a negative return on equity of 97,487.15%. The firm had revenue of $27.48 million during the quarter, compared to analysts’ expectations of $34.09 million. Research analysts forecast that Urogen Pharma will post -3.12 EPS for the current year.

Insiders Place Their Bets

In other Urogen Pharma news, insider Mark Schoenberg sold 10,000 shares of the firm’s stock in a transaction on Wednesday, November 19th. The stock was sold at an average price of $25.00, for a total value of $250,000.00. Following the completion of the sale, the insider owned 139,025 shares of the company’s stock, valued at approximately $3,475,625. This trade represents a 6.71% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Chris Degnan sold 2,203 shares of the business’s stock in a transaction on Wednesday, October 8th. The stock was sold at an average price of $16.85, for a total transaction of $37,120.55. Following the sale, the chief financial officer owned 2,280 shares in the company, valued at $38,418. The trade was a 49.14% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 4.70% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Urogen Pharma

Several large investors have recently added to or reduced their stakes in URGN. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Urogen Pharma by 216.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,360,524 shares of the company’s stock worth $48,227,000 after purchasing an additional 2,983,368 shares in the last quarter. Paradigm Biocapital Advisors LP purchased a new stake in Urogen Pharma during the third quarter worth approximately $84,111,000. RA Capital Management L.P. acquired a new stake in shares of Urogen Pharma in the first quarter worth $35,461,000. Soleus Capital Management L.P. purchased a new position in shares of Urogen Pharma in the 2nd quarter valued at $29,934,000. Finally, Vestal Point Capital LP raised its stake in shares of Urogen Pharma by 32.1% in the 1st quarter. Vestal Point Capital LP now owns 2,152,957 shares of the company’s stock valued at $23,812,000 after acquiring an additional 522,957 shares during the period. 91.29% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on URGN. D. Boral Capital restated a “buy” rating and issued a $25.00 price target on shares of Urogen Pharma in a research report on Monday, October 27th. Wall Street Zen upgraded shares of Urogen Pharma from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price target on shares of Urogen Pharma in a report on Monday, October 27th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Urogen Pharma in a research report on Wednesday, October 8th. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $32.00.

Urogen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.